TraceLink says revenues rising fast on life sciences demand

Serialization projects for life sciences companies have driven a two-thirds rise in revenues at TraceLink, which says it added 71 new customers in the first quarter.

With pharma companies, contract manufacturers and other supply chain partners now facing serialization/track and trace requirements on both sides of the Atlantic and multiple other jurisdictions worldwide, TraceLink is growing fast, almost doubling its headcount in the last year.

"We're off to a fantastic start in 2016, with momentum accelerating rapidly as compliance deadlines near for life sciences companies," said Shabbir Dahod, TraceLink's president and chief executive, referring to requirements such as the Falsified Medicines Directive (FMD) in the EU, the Drug Supply Chain Security Act (DSCSA) in the US and India's initiative for coding exported pharmaceuticals.

He also claims that while some of TraceLink's competitors are "increasingly unable to deliver on the promises they've been making," the company's customers are "already operating at scale, shipping serialized products into eight countries."

Among the companies achievements in the first quarter was the completion of a DSCSA data exchange pilot between top-five pharma manufacturers and one of the 'big three' wholesalers, as well as product master data and product pack data upload certification tests with the European Medicines Verification Organization (EMVO).